

1 **An expanded population of CD8<sup>dim</sup> T cells with features of mitochondrial**  
2 **dysfunction and senescence is associated with persistent HIV-associated**  
3 **Kaposi's sarcoma under ART**

4 Genevieve T CLUTTON\*¶, Ann Marie K WEIDEMAN†, Nilu P GOONETILLEKE\*‡,  
5 Toby MAURER§

6 \*Department of Microbiology & Immunology, UNC Chapel Hill School of Medicine,  
7 Chapel Hill, North Carolina 27599, USA

8 †Department of Biostatistics and Center for AIDS Research, UNC Chapel Hill, Chapel  
9 Hill, North Carolina 27599, USA

10 ‡UNC HIV Cure Center, UNC Institute of Global Health and Infectious Diseases, Chapel  
11 Hill, North Carolina 27599, USA

12 §Department of Dermatology, Indiana University, Indiana, USA

13 ¶Corresponding author. Email: [gen\\_clutton@med.unc.edu](mailto:gen_clutton@med.unc.edu)

14 **Abstract**

15 HIV-associated Kaposi's sarcoma (KS), which is caused by Kaposi's sarcoma-associated  
16 herpesvirus, usually arises in the context of uncontrolled HIV replication and  
17 immunosuppression. However, disease occasionally persists in individuals with durable HIV  
18 viral suppression and CD4 T cell recovery under anti-retroviral therapy (ART). The  
19 underlying mechanisms associated with this persistence are unclear. Suppression of viral  
20 infections can be mediated by CD8 T cells that detect infected cells via their T cell receptor  
21 and the CD8 co-receptor. However, CD8 T cells exhibit signs of functional exhaustion in  
22 untreated HIV infection that may not be fully reversed under ART. To investigate whether  
23 persistent KS under ART was associated with phenotypic and functional perturbations of  
24 CD8 T cells, we performed a cross-sectional study comparing HIV-infected individuals with  
25 persistent KS under effective ART (HIV+ KS+) to HIV-infected individuals receiving  
26 effective ART with no documented history of KS (HIV+ KS<sup>neg</sup>). A subset of T cells with  
27 low cell surface expression of CD8 ("CD8<sup>dim</sup> T cells") was expanded in HIV+ KS+  
28 compared with HIV+ KS<sup>neg</sup> participants. Relative to CD8<sup>bright</sup> T cells, CD8<sup>dim</sup> T cells  
29 exhibited signs of senescence (CD57) and mitochondrial perturbations (PGC-1 $\alpha$ ,  
30 MitoTracker) ex vivo. Mitochondrial activity (MitoTracker) was also reduced in  
31 proliferating CD8<sup>dim</sup> T cells. These findings indicate that an expanded CD8<sup>dim</sup> T cell  
32 population displaying features of senescence and mitochondrial dysfunction is associated  
33 with KS persistence under ART. CD8 co-receptor down-modulation may be symptomatic  
34 of ongoing disease.

35 **Running title: CD8<sup>dim</sup> T cells expanded in HIV-associated KS**

36 Keywords: T cells; CD8 co-receptor; KSHV; Kaposi's sarcoma; Tumor immunity; HIV;

37 Metabolism; Senescence; Mitochondria; MitoTracker; PGC-1 $\alpha$ ; Proliferation.

38

39 Funding: This study was supported by a Young Investigator Pilot Award awarded to G.T.C.  
40 by the AIDS and Cancer Specimen Resource, funded by the National Cancer Institute (UM1  
41 CA181255). Initial sample collection was supported by NIH grants U01 AI117844, U01  
42 AI095052, and R01 HL132791. The UNC Flow Cytometry Core Facility is supported in part  
43 by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger  
44 Comprehensive Cancer Center and by the Center for AIDS Research award number  
45 5P30AI050410. Statistical expertise was provided by the University of North Carolina at  
46 Chapel Hill Center for AIDS Research, an NIH funded program P30 AI050410. The content  
47 is solely the responsibility of the authors and does not necessarily represent the official views  
48 of the National Institutes of Health.

49

50 Abbreviations used in this article

51 ART (HIV) Anti-retroviral therapy

52 CFSE carboxyfluorescein succinimidyl ester

53 KS Kaposi's sarcoma

54 KSHV Kaposi's sarcoma-associated herpesvirus, also known as HHV-8

55 MTD R MitoTracker® Deep Red

56 PBMC Peripheral blood mononuclear cells

57 PHA Phytohaemagglutinin

58 TCR T cell receptor

59

60

## 61 **Introduction**

62 Kaposi's sarcoma (KS), a cancer of epithelial and endothelial cells characterized by dark  
63 plaques and nodules, is a common AIDS-related morbidity in individuals with untreated HIV  
64 infection <sup>[1]</sup>. However, while the etiologic agent of KS, Kaposi's sarcoma-associated  
65 herpesvirus (KSHV), generates a lifelong infection, it rarely causes disease in  
66 immunocompetent individuals. The introduction of HIV antiretroviral therapy (ART), and  
67 resulting immune recovery in treated individuals, has been accompanied by a steep decline  
68 in HIV-associated KS cases <sup>[2, 3]</sup>. However, a minority of HIV-infected KSHV-seropositive  
69 individuals experience persistent KS despite durable HIV suppression and CD4 T cell  
70 recovery under ART <sup>[4-6]</sup>. The underlying causes of this failure to achieve KS remission are  
71 not currently understood. The recent discovery that latent KSHV can be reactivated by  
72 proteins from SARS-CoV-2 and some anti-COVID-19 drugs further underscores the need to  
73 better understand the control and pathogenesis of KS <sup>[7]</sup>.

74 CD8 T cells are major mediators of anti-viral immunity, detecting virus-infected cells via  
75 the T cell receptor (TCR) and CD8-co-receptor. KSHV-infected individuals harbor CD8 T  
76 cells capable of secreting antiviral cytokines and killing cells expressing KSHV antigens in  
77 vitro <sup>[8-14]</sup>. These KSHV-specific CD8 T cells are detected at higher frequencies in KSHV-  
78 seropositive individuals who do not have KS compared with individuals with active disease  
79 <sup>[14]</sup>. Collectively, these observations suggest that in immunocompetent individuals, CD8 T  
80 cells may play a lifelong role in preventing KSHV from causing disease. However, during  
81 untreated progressive HIV infection, T cells exhibit signs of functional exhaustion that may  
82 not be fully reversed by ART <sup>[15-19]</sup>. Notably, these defects include metabolic perturbations

83 such as impaired mitochondrial oxidative phosphorylation and increased reliance on  
84 glycolysis [20, 21]. Mitochondrial metabolism is crucial for lasting CD8 T cell control of viral  
85 infections: while effector T cells upregulate glycolysis to rapidly generate ATP, memory T  
86 cells use mitochondrial oxidative phosphorylation to support their long-term persistence [22-  
87 26]. Indeed, loss of mitochondrial mass is associated with senescence, a state where T cells  
88 lose proliferative capacity [27]. Defects in CD8 T cell metabolic fitness in HIV-infected  
89 individuals on ART could be particularly detrimental in the tumor microenvironment, where  
90 rapidly proliferating malignant cells create an environment of hypoxia and mitochondrial  
91 stress [28-30].

92 We investigated the possibility that altered CD8 T cell phenotype and metabolism could be  
93 associated with persistent KS in HIV-infected individuals on ART by comparing HIV-  
94 infected individuals with and without KS. We observed an elevated frequency of CD8<sup>dim</sup> T  
95 cells in individuals with HIV-associated KS. These cells expressed elevated levels of the  
96 senescence marker CD57, lower levels of the mitochondrial master-regulator PGC-1 $\alpha$ , and  
97 exhibited reduced mitochondrial activity. Persistent KS is therefore associated with the  
98 expansion of a subset of CD8 T cells with metabolic hallmarks of senescence.

99

## 100 **Materials and Methods**

### 101 *Study participants:*

102 HIV-1-infected participants with biopsy-confirmed KS (“HIV+ KS+”) were recruited from  
103 primary care practices in San Francisco and the adjacent counties, UCLA-related primary  
104 care clinics, and the Study of the Consequences of the Protease Inhibitor Era (SCOPE).  
105 Participants had received ART (including protease inhibitors, NNRTIs, and early integrase  
106 inhibitors) and maintained plasma viral loads <75 copies/ml for  $\geq 2$  years. CD4 T cell counts  
107 were  $\geq 340/\mu\text{l}$ . All participants had stage 1 tumors according to ACTG criteria (tumor  
108 confined to skin and/or lymph nodes and/or minimal oral disease) <sup>[31]</sup>. The study was  
109 approved by the Institutional Review Board of the University of California, San Francisco  
110 (approval no. 10-02850). HIV-1-infected participants with no documented history of KS  
111 (“HIV+ KS<sup>neg</sup>”) were recruited from the UNC HIV Clinical Trials Unit. Participants had  
112 received ART for  $\geq 2$  years and maintained plasma viral loads <50 copies/ml and CD4 T cell  
113 counts >300/ $\mu\text{l}$  for  $\geq 6$  months. Participant characteristics are detailed in Table 1. Initial  
114 collection of UNC samples was approved by the UNC Institutional Review Board (ethics  
115 numbers 11-0228; 14-0741; and 15-1626). Retrospective use of all samples was approved  
116 by the UNC Institutional Review Board (ethics number 17-2415).

### 117 *CD8 T cell phenotyping:*

118 Cryopreserved peripheral blood mononuclear cells (PBMC) were rested in R10 medium  
119 (RPMI 1640 supplemented with 10% fetal bovine serum; penicillin/streptomycin; 2 mM L-  
120 glutamine; 10 mM sodium pyruvate; and 10 mM HEPES) at 37°C overnight. PBMC were

121 stained with Zombie NIR viability dye, then cell surface antibodies CD3-PerCP-Cy5.5  
122 (clone UCHT1); CD4-PE-Cy5 (OKT4); CD8-Brilliant Violet 510 (SK1); CD14 (M5E2),  
123 CD16 (3G8), CD19 (HIB19), and CD56 (HCD56)-Brilliant Violet 650; CD45RO-PE  
124 (UCHL1); and CD57-PE-Dazzle 594 (HNK-1) (all Biolegend). Cells were stained  
125 intracellularly with T-bet-Brilliant Violet 421 (4B10; Biolegend); Eomes-eFluor 660  
126 (WD1928; eBioscience); polyclonal anti-PGC-1 $\alpha$  antibody (Santa Cruz Biotechnology); and  
127 PE-Cy7 secondary antibody. Samples were acquired on an LSRII flow cytometer and  
128 analyzed using FlowJo 10 (BD Biosciences). Live lymphocytes were defined by dim  
129 staining with Zombie viability dye, forward scatter height vs area (to identify single events),  
130 and forward scatter versus side scatter. CD8 T lymphocytes were defined as CD3+ CD4-  
131 CD14/16/19/56- and CD8 bright or dim. For phenotypic markers, positive events were gated  
132 using fluorescence minus one controls (Supplementary Figure 1).

133 **Table 1: Participant Characteristics**

	<b>HIV+ KS+ (n = 8)</b>	<b>HIV+ KS<sup>neg</sup> (n = 12)</b>
Age in years; median (range)	57 (35 – 65)	48 (33 – 66)
Male sex	8/8	9/12
Viral load (copies/ml)	<70 (<70 - 97)	<50
CD4 count (cells/ $\mu$ l)	677 (340 – 1331)	769 (491 – 1289)
KS stage	ACTG stage 1	N/A

134

135 *CD8 T cell proliferation:*

136 Cryopreserved PBMC were rested overnight, then pulsed under rotation with 5  $\mu$ M  
137 carboxyfluorescein succinimidyl ester (CFSE, Biolegend). Staining was quenched with ice-

138 cold R10. Cells were stimulated with vehicle (0.5% DMSO) or 3  $\mu$ g/ml phytohaemagglutinin  
139 (PHA, Sigma) for 5 days at 37°C. PBMC were stained with Zombie NIR; CD3-PE-Cy7;  
140 CD4-BV421; CD8-BV510; CD14, CD16, CD19, and CD56-BV650 (clones as previously;  
141 Biolegend). To assess mitochondrial polarization, cells were stained with 25 nM  
142 MitoTracker® Deep Red (MTDR, Molecular Probes) at 37°C. Cells were acquired on an  
143 LSR Fortessa and analyzed using FlowJo 10 and Modfit LT 4 (Verity Software House).  
144 Proliferation was assessed using proliferation index, defined as the mean number of  
145 proliferative cycles undergone by each proliferating cell [32]. MTDR<sup>high</sup> cells were gated  
146 using a previously described method [33]. Briefly, after excluding outliers (the brightest and  
147 dimmest 0.1% of events), the fluorescence intensities of the brightest and dimmest cells were  
148 used to calculate the fluorescence range (brightest – dimmest). Cells that fell within the top  
149 90% of this range were considered MTDR<sup>high</sup> (Supplementary Figure 2).

150 *Statistical analysis:*

151 Data were analyzed using GraphPad Prism version 8. Between-group differences were  
152 analyzed using an exact, two-sided Mann-Whitney U test. Within-individual differences  
153 between CD8<sup>bright</sup> and CD8<sup>dim</sup> T cells were analyzed using an exact, two-sided Wilcoxon  
154 signed-rank test. The monotonic (strictly increasing or decreasing) relationship between  
155 variables such as CD8<sup>dim</sup> percentage and proliferation index was assessed using Spearman's  
156 rank correlation coefficient.


157

## 158 **Results**

159 *CD8<sup>dim</sup> T cells are expanded in HIV+ individuals with persistent KS, and exhibit features of*  
160 *senescence*

161 We compared the phenotype of CD8 T cells between HIV-infected individuals with  
162 persistent KS under ART (HIV+ KS+) and HIV-infected individuals receiving ART with no  
163 documented history of KS (HIV+ KS<sup>neg</sup>). CD8 T cells were defined as CD3<sup>+</sup> CD8<sup>+</sup> CD4-  
164 CD14/CD16/CD56- to exclude NKT cells (Supplementary Figure 1). We observed two  
165 populations of CD8 T cells: a CD8<sup>bright</sup> subset with high cell surface expression of CD8 and  
166 a CD8<sup>dim</sup> subset with lower surface expression (Fig. 1A). CD3 $\epsilon$ , which forms part of the  
167 TCR complex, was also expressed at a lower level on the surface of CD8<sup>dim</sup> cells compared  
168 with CD8<sup>bright</sup> cells (median of differences = -4358 MFI; Wilcoxon signed-rank test p =  
169 0.007; Supplementary Figure 3). The CD8<sup>dim</sup> subset was significantly expanded, as a  
170 percentage of total CD8 T cells, in HIV+ KS+ compared with HIV+ KS<sup>neg</sup> participants  
171 (difference of medians = 12.28%; Mann-Whitney test p = 0.0006; Fig. 1B). Since highly  
172 differentiated T cells accumulate during chronic untreated infections [34, 35], we next  
173 compared the differentiation state of CD8<sup>bright</sup> and CD8<sup>dim</sup> cells within participants. CD57  
174 expression was higher on CD8<sup>dim</sup> than CD8<sup>bright</sup> T cells (median of differences = 8%;  
175 Wilcoxon signed-rank test p = 0.008), indicating that late-differentiated or senescent cells  
176 were overrepresented in the CD8<sup>dim</sup> population (Fig. 1C and Supplementary Figure 3).  
177 Supporting this observation, Eomesodermin (Eomes), a transcription factor expressed in  
178 terminal memory cells, was expressed in a higher percentage of CD8<sup>dim</sup> than CD8<sup>bright</sup> cells  
179 (median of differences = 13.5%; Wilcoxon signed-rank test p = 0.008, Fig. 1D and

180 Supplementary Figure 3) [36, 37]. T-bet, a transcription factor expressed by effector cells, was  
181 expressed at similar levels in CD8<sup>bright</sup> and CD8<sup>dim</sup> cells (Supplementary Figure 3).



182

183 **Figure 1. CD8<sup>dim</sup> cells with low mitochondrial activity are expanded in individuals**

184 **with persistent KS. A) Representative plots showing CD8<sup>bright</sup> and CD8<sup>dim</sup> T cells in a**

185 HIV+ KS<sup>neg</sup> and a HIV+ KS<sup>+</sup> participant. B) The frequency of CD8<sup>dim</sup> T cells (as a  
186 percentage of total CD8 T cells) is significantly elevated in HIV+ individuals with  
187 persistent KS under ART (KS<sup>+</sup>; n = 7) compared with the KS<sup>neg</sup> group (n = 8) (difference  
188 of medians= 12.28%; Mann-Whitney test). C) A significantly higher percentage of CD8<sup>dim</sup>  
189 T cells express CD57 compared with CD8<sup>bright</sup> T cells (median of differences = 8%;  
190 Wilcoxon signed-rank test). D) A significantly higher percentage of CD8<sup>dim</sup> T cells  
191 express Eomes compared with CD8<sup>bright</sup> T cells (median of differences = 13.5%; Wilcoxon  
192 signed-rank test). E) Expression of the mitochondrial master regulator PGC-1 $\alpha$  is  
193 significantly reduced in CD8<sup>dim</sup> T cells (median of differences = -789 MFI; Wilcoxon  
194 signed-rank test). F) The frequency of MitoTracker Deep Red high cells is significantly  
195 lower for CD8<sup>dim</sup> T cells compared with CD8<sup>bright</sup> T cells (median of differences = -8.99%;  
196 Wilcoxon signed-rank test). Gray open squares, HIV+ KS<sup>+</sup> participants; black circles,  
197 HIV+ KS<sup>neg</sup> participants.

198

### 199 *CD8<sup>dim</sup> T cells have an altered mitochondrial phenotype*

200 The development, persistence, and recall function of memory CD8 T cells is highly  
201 dependent on mitochondrial metabolism [24, 38]. Compared with CD8<sup>bright</sup> T cells, expression  
202 of the mitochondrial master regulator PGC-1 $\alpha$  was significantly reduced in CD8<sup>dim</sup> T cells  
203 (median of differences = -789 MFI; Wilcoxon signed-rank test p = 0.001; Fig. 1E). To  
204 further investigate mitochondrial phenotype in CD8<sup>bright</sup> vs CD8<sup>dim</sup> T cells, we used  
205 MitoTracker® Deep Red (MTDR), which selectively binds actively respiring mitochondria  
206 [39]. MTDR<sup>high</sup> cells were defined using a previously described objective gating strategy ([33];

207 Supplementary Figure 2). The frequency of MTDR<sup>high</sup> cells was lower in the CD8<sup>dim</sup> T cell  
208 population than CD8<sup>bright</sup> T cells (median of differences = -8.99%; Wilcoxon signed-rank  
209 test  $p = 0.002$ ; Fig. 1F). These observations indicate that individuals with HIV-associated  
210 KS have an expanded population of CD8<sup>dim</sup> T cells with a highly differentiated/senescent  
211 phenotype and reduced mitochondrial activity.


212

### 213 *Mitochondrial activity is reduced in CD8<sup>dim</sup> proliferating cells*

214 We next examined whether cell surface expression of the CD8 co-receptor was related to  
215 replicative capacity and mitochondrial activity in proliferating cells. PBMC were stimulated  
216 with the polyclonal stimulus PHA for five days and proliferation was measured by CFSE  
217 dilution (Fig. 2A). Proliferative capacity was reported as proliferation index (the mean  
218 number of proliferative cycles undergone by each responding cell).

219 CD8 T cells that had proliferated (CFSE<sup>low</sup>) exhibited greater mitochondrial activity (% of  
220 cells MTDR<sup>high</sup>) than non-proliferating (CFSE<sup>high</sup>) cells (median of differences = 23.25%;  
221 Wilcoxon signed-rank test  $p = 0.002$ ; Fig. 2B). There was a strong positive correlation  
222 between mitochondrial activity of all CD8 T cells and proliferation index at day five,  
223 demonstrating the importance of mitochondrial respiration to CD8 T cell proliferation ( $r_s =$   
224  $0.75$ ,  $p = 0.017$ ; Fig. 2C) <sup>[26]</sup>. Conversely, there was a strong negative correlation between  
225 mitochondrial activity of all CD8 T cells and the percentage of CD8<sup>dim</sup> T cells in the culture  
226 at five days ( $r_s = -0.75$ ,  $p = 0.017$ ; Fig. 2D), suggesting that low CD8 expression is associated  
227 with reduced mitochondrial activity. Further supporting this hypothesis, CD8<sup>dim</sup> cells that

228 had proliferated exhibited lower mitochondrial activity (% MTDR<sup>high</sup>) than CD8<sup>bright</sup> cells  
229 that had proliferated (median of differences = -23.35%; Wilcoxon signed-rank test  $p = 0.002$ ;  
230 Fig. 2E). There was also evidence of a moderate negative correlation between the percentage  
231 of CD8<sup>dim</sup> T cells in the culture and proliferation index ( $r_s = -0.61$ ,  $p = 0.067$ ; Fig. 2F).  
232 Collectively these results indicate that low surface expression of CD8 is associated with  
233 reduced mitochondrial respiration and replicative capacity of proliferating CD8 T cells.



234

235 **Figure 2. Mitochondrial activity is reduced in CD8<sup>dim</sup> proliferating cells.**

236 A) Histograms showing CFSE dilution in unstimulated and PHA-stimulated CD8 T cells.

237 B) MitoTracker Deep Red (MTDR) fluorescence in PHA-stimulated proliferating

238 (CFSE<sup>low</sup>) cells. A significantly higher percentage of proliferating (CFSE<sup>low</sup>) CD8 T cells

239 are MTDR<sup>high</sup> compared with non-proliferating (CFSE<sup>high</sup>) CD8 T cells, indicating that

240 proliferating cells have higher mitochondrial activity ( $n = 10$ ; median of differences =

241 23.25%; Wilcoxon signed-rank test). C) Positive association between mitochondrial  
242 activity (% MTDR<sup>high</sup>) of all CD8 T cells in the culture and the proliferation index of  
243 proliferating cells in response to PHA stimulation (Spearman correlation). D) Negative  
244 association between mitochondrial activity and the frequency of CD8<sup>dim</sup> T cells following  
245 stimulation with PHA (Spearman correlation). E) The frequency of MTDR<sup>high</sup> cells,  
246 comparing CD8<sup>bright</sup> and CD8<sup>dim</sup> proliferating (CFSE<sup>low</sup>) cells. CD8<sup>dim</sup> proliferating cells  
247 are significantly less likely to be MTDR<sup>high</sup>, indicating lower mitochondrial activity  
248 (median of differences = -23.35%; Wilcoxon signed-rank test). F) Proliferation index of  
249 PHA-stimulated CD8 T cells versus the frequency of CD8<sup>dim</sup> T cells in the culture  
250 (Spearman correlation). Gray open squares, HIV+ KS+ participants; black circles, HIV+  
251 KS<sup>neg</sup> participants.

252

## 253 **Discussion**

254 The underlying causes of persistent KS in a minority of HIV-infected individuals with  
255 durable viral suppression and CD4 T cell recovery under ART are unknown. Here, we have  
256 identified an expanded population of CD8<sup>dim</sup> T cells with phenotypic characteristics of  
257 senescence and mitochondrial dysfunction in these individuals.

258 The CD8 co-receptor amplifies signals through the TCR [40, 41]. Following antigenic  
259 stimulation (e.g. by a virus-infected cell), CD8, along with the TCR, is downregulated from  
260 the cell surface, possibly to limit the strength or duration of signaling [42-44]. This suggests  
261 that the expansion of CD8<sup>dim</sup> T cells may be a response to high and/or persistent antigen  
262 stimulation. Supporting this hypothesis, elevated frequencies of CD8<sup>dim</sup> T cells have been  
263 reported during acute HIV infection, and in children exposed to a high cumulative pathogen  
264 burden during the first years of life [45, 46]. Our observation that CD8<sup>dim</sup> T cells are also  
265 expanded in individuals with persistent KS under ART supports the notion that CD8  
266 downregulation is a general phenomenon in settings of unresolved infection.

267 Chronic viral infections are also associated with CD8 T cell terminal differentiation and/or  
268 senescence<sup>[47]</sup>. Senescent CD8 T cells exhibit reduced expression of PGC-1 $\alpha$ , the master-  
269 regulator of mitochondrial biogenesis, and lower mitochondrial activity [27, 48]. Conversely,  
270 forced expression of PGC-1 $\alpha$  promotes robust CD8 T cell memory responses [49]. These  
271 observations underscore the importance of mitochondrial respiration for long-term CD8 T  
272 cell anti-viral function. In the setting of persistent KS, we observed that the expanded CD8<sup>dim</sup>  
273 T cell population expressed high levels of Eomesodermin and CD57, proteins respectively

274 associated with terminal differentiation and senescence, and had reduced expression of PGC-  
275 1 $\alpha$ . CD8<sup>dim</sup> cells also contained fewer respiring mitochondria both *ex vivo* and when  
276 proliferating. Our data suggest that mitochondrial dysfunction may underlie the  
277 accumulation of senescent CD8 T cells that has previously been reported in KS <sup>[34]</sup>; however,  
278 this hypothesis must be tested in future studies. It is unclear from our current data whether  
279 CD8 expression directly regulates mitochondrial activity in CD8 T cells.

280 A key question is whether the CD8<sup>dim</sup> T cells we observed are specific for KSHV, for HIV,  
281 or for other persistent viral infections such as CMV, which is highly seroprevalent in HIV-  
282 infected individuals <sup>[50]</sup>. It is possible that CD8 down-modulation could be driven by multiple  
283 concurrent infections, by ongoing immune activation, or by a combination of factors. In this  
284 initial study, we were unable to determine whether the CD8<sup>dim</sup> T cells we observed were  
285 KSHV-specific, as KSHV is a large virus, and immunoprevalent epitopes eliciting responses  
286 in a high percentage of seropositive individuals have not yet been identified. The question  
287 of the antigen specificity of CD8<sup>dim</sup> T cells will be the subject of subsequent investigations.

288 Our work has some limitations. As this was an observational study, we were unable to  
289 determine whether the expansion of CD8<sup>dim</sup> T cells plays a causative role in the failure to  
290 control KSHV under ART or is a consequence of this lack of suppression. Due to lack of  
291 available tissue, we were unable to assess whether CD8 T cells infiltrating the tumor  
292 microenvironment also exhibit a CD8<sup>dim</sup> phenotype. This question, together with the antigen  
293 specificity of CD8<sup>dim</sup> T cells and a direct examination of their functional profile, is the  
294 subject of ongoing investigations. If KSHV-specific CD8 T cells infiltrating the tumor

295 microenvironment express low levels of CD8 and exhibit reduced mitochondrial activity,  
296 this will have important implications for immunotherapeutic approaches to KS treatment.

297

298

## 299 **Acknowledgements**

300 Author contributions: The manuscript was written by G.T.C., A.M.W., N.P.G., and T.M.  
301 G.T.C. and N.P.G. contributed to study design. G.T.C. performed experimentation and  
302 collection of data. G.T.C. and A.M.W. performed the statistical analyses. G.T.C. acquired  
303 funding for the study. T.M. facilitated participant recruitment and sample collection. All  
304 authors provided review of the final manuscript. We thank Joann Kuruc and Cynthia Gay  
305 for their work recruiting participants to UNC cohorts that were retrospectively utilized for  
306 this study.

307 Conflicts of interest: There are no conflicts of interest.

308

## 309 **References**

- 310 1. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, Bhatia K, Uldrick TS, Yarchoan R,  
311 Goedert JJ, Engels EA. **Cancer burden in the HIV-infected population in the United States.** *J Natl*  
312 *Cancer Inst* 2011; 103(9):753-762.
- 313 2. Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. **Trends in Kaposi's sarcoma and non-**  
314 **Hodgkin's lymphoma incidence in the United States from 1973 through 1998.** *J Natl Cancer Inst*  
315 2002; 94(16):1204-1210.
- 316 3. Franceschi S, Maso LD, Rickenbach M, Polesel J, Hirschel B, Cavassini M, Bordoni A, Elzi L, Ess S,  
317 Jundt G, Mueller N, Clifford GM. **Kaposi sarcoma incidence in the Swiss HIV Cohort Study before**  
318 **and after highly active antiretroviral therapy.** *Br J Cancer* 2008; 99(5):800-804.
- 319 4. Maurer T, Ponte M, Leslie K. **HIV-associated Kaposi's sarcoma with a high CD4 count and a low**  
320 **viral load.** *N Engl J Med* 2007; 357(13):1352-1353.
- 321 5. Mani D, Neil N, Israel R, Aboulaflia DM. **A retrospective analysis of AIDS-associated Kaposi's**  
322 **sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300**  
323 **cells/mm(3).** *Journal of the International Association of Physicians in AIDS Care (Chicago, Ill :*  
324 *2002)* 2009; 8(5):279-285.
- 325 6. von Braun A, Braun DL, Kamarachev J, Gunthard HF. **New onset of kaposi sarcoma in a human**  
326 **immunodeficiency virus-1-infected homosexual man, despite early antiretroviral treatment,**  
327 **sustained viral suppression, and immune restoration.** *Open forum infectious diseases* 2014;  
328 1(1):ofu005.
- 329 7. Chen J, Dai L, Barrett L, James J, Plaisance-Bonstaff K, Post SR, Qin Z. **SARS-CoV-2 proteins and**  
330 **anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus.** *Communications biology*  
331 2021; 4(1):682.

- 332 8. Osman M, Kubo T, Gill J, Neipel F, Becker M, Smith G, Weiss R, Gazzard B, Boshoff C, Gotch F.  
333 **Identification of human herpesvirus 8-specific cytotoxic T-cell responses.** *J Virol* 1999;  
334 73(7):6136-6140.
- 335 9. Bihl F, Narayan M, Chisholm JV, 3rd, Henry LM, Suscovich TJ, Brown EE, Welzel TM, Kaufmann  
336 DE, Zaman TM, Dollard S, Martin JN, Wang F, Scadden DT, Kaye KM, Brander C. **Lytic and latent**  
337 **antigens of the human gammaherpesviruses Kaposi's sarcoma-associated herpesvirus and**  
338 **Epstein-Barr virus induce T-cell responses with similar functional properties and memory**  
339 **phenotypes.** *J Virol* 2007; 81(9):4904-4908.
- 340 10. Bihl F, Berger C, Chisholm JV, 3rd, Henry LM, Bertisch B, Trojan A, Nadal D, Speck RF, Flepp M,  
341 Brander C, Mueller NJ, Swiss HIVCS. **Cellular immune responses and disease control in acute**  
342 **AIDS-associated Kaposi's sarcoma.** *AIDS* 2009; 23(14):1918-1922.
- 343 11. Robey RC, Lagos D, Gratrix F, Henderson S, Matthews NC, Vart RJ, Bower M, Boshoff C, Gotch  
344 FM. **The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is**  
345 **skewed towards early and late lytic antigens.** *PLoS One* 2009; 4(6):e5890.
- 346 12. Lepone L, Rappocciolo G, Knowlton E, Jais M, Piazza P, Jenkins FJ, Rinaldo CR. **Monofunctional**  
347 **and polyfunctional CD8+ T cell responses to human herpesvirus 8 lytic and latency proteins.**  
348 *Clinical and vaccine immunology : CVI* 2010; 17(10):1507-1516.
- 349 13. Lepone LM, Rappocciolo G, Piazza PA, Campbell DM, Jenkins FJ, Rinaldo CR. **Regulatory T Cell**  
350 **Effect on CD8(+) T Cell Responses to Human Herpesvirus 8 Infection and Development of**  
351 **Kaposi's Sarcoma.** *AIDS Res Hum Retroviruses* 2017; 33(7):668-674.
- 352 14. Lambert M, Gannage M, Karras A, Abel M, Legendre C, Kerob D, Agbalika F, Girard PM, Lebbe  
353 C, Caillat-Zucman S. **Differences in the frequency and function of HHV8-specific CD8 T cells**  
354 **between asymptomatic HHV8 infection and Kaposi sarcoma.** *Blood* 2006; 108(12):3871-3880.

- 355 15. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie  
356 AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM,  
357 Goulder PJ, Klenerman P, Ahmed R, Freeman GJ, Walker BD. **PD-1 expression on HIV-specific T**  
358 **cells is associated with T-cell exhaustion and disease progression.** *Nature* 2006; 443(7109):350-  
359 354.
- 360 16. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, Boulassel MR, Delwart  
361 E, Sepulveda H, Balderas RS, Routy JP, Haddad EK, Sekaly RP. **Upregulation of PD-1 expression on**  
362 **HIV-specific CD8+ T cells leads to reversible immune dysfunction.** *Nature medicine* 2006;  
363 12(10):1198-1202.
- 364 17. Day CL, Kiepiela P, Leslie AJ, van der Stok M, Nair K, Ismail N, Honeyborne I, Crawford H,  
365 Coovadia HM, Goulder PJ, Walker BD, Klenerman P. **Proliferative capacity of epitope-specific CD8**  
366 **T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type**  
367 **1 infection.** *J Virol* 2007; 81(1):434-438.
- 368 18. Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, Hallahan CW, Cogliano-  
369 Shutta NA, Metcalf JA, McLaughlin M, Kwan R, Mican JM, Davey RT, Jr., Connors M. **Defective**  
370 **human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and**  
371 **cytotoxicity are not restored by antiretroviral therapy.** *J Virol* 2009; 83(22):11876-11889.
- 372 19. Gaiha GD, McKim KJ, Woods M, Pertel T, Rohrbach J, Barteneva N, Chin CR, Liu D, Soghoian  
373 DZ, Cesa K, Wilton S, Waring MT, Chicoine A, Doering T, Wherry EJ, Kaufmann DE, Lichterfeld M,  
374 Brass AL, Walker BD. **Dysfunctional HIV-Specific CD8(+) T Cell Proliferation Is Associated with**  
375 **Increased Caspase-8 Activity and Mediated by Necroptosis.** *Immunity* 2014; 41(6):1001-1012.
- 376 20. Korencak M, Byrne M, Richter E, Schultz BT, Juszczak P, Ake JA, Ganesan A, Okulicz JF, Robb  
377 ML, de Los Reyes B, Winning S, Fandrey J, Burgess TH, Esser S, Michael NL, Agan BK, Streeck H.

- 378 **Effect of HIV infection and antiretroviral therapy on immune cellular functions.** *JCI Insight* 2019;  
379 4(12).
- 380 21. Angin M, Volant S, Passaes C, Lecuroux C, Monceaux V, Dillies M-A, Valle-Casuso JC, Pancino  
381 G, Vaslin B, Le Grand R, Weiss L, Goujard C, Meyer L, Boufassa F, Müller-Trutwin M, Lambotte O,  
382 Sáez-Cirión A. **Metabolic plasticity of HIV-specific CD8+ T cells is associated with enhanced**  
383 **antiviral potential and natural control of HIV-1 infection.** *Nature Metabolism* 2019; 1(7):704-716.
- 384 22. Cham CM, Gajewski TF. **Glucose availability regulates IFN-gamma production and p70S6**  
385 **kinase activation in CD8+ effector T cells.** *J Immunol* 2005; 174(8):4670-4677.
- 386 23. Jacobs SR, Herman CE, Maciver NJ, Wofford JA, Wieman HL, Hammen JJ, Rathmell JC. **Glucose**  
387 **uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and**  
388 **independent pathways.** *J Immunol* 2008; 180(7):4476-4486.
- 389 24. van der Windt GJ, Everts B, Chang CH, Curtis JD, Freitas TC, Amiel E, Pearce EJ, Pearce EL.  
390 **Mitochondrial respiratory capacity is a critical regulator of CD8+ T cell memory development.**  
391 *Immunity* 2012; 36(1):68-78.
- 392 25. van der Windt GJ, O'Sullivan D, Everts B, Huang SC, Buck MD, Curtis JD, Chang CH, Smith AM,  
393 Ai T, Faubert B, Jones RG, Pearce EJ, Pearce EL. **CD8 memory T cells have a bioenergetic**  
394 **advantage that underlies their rapid recall ability.** *Proc Natl Acad Sci U S A* 2013.
- 395 26. Chang CH, Curtis JD, Maggi LB, Jr., Faubert B, Villarino AV, O'Sullivan D, Huang SC, van der  
396 Windt GJ, Blagih J, Qiu J, Weber JD, Pearce EJ, Jones RG, Pearce EL. **Posttranscriptional control of**  
397 **T cell effector function by aerobic glycolysis.** *Cell* 2013; 153(6):1239-1251.
- 398 27. Callender LA, Carroll EC, Bober EA, Akbar AN, Solito E, Henson SM. **Mitochondrial mass**  
399 **governs the extent of human T cell senescence.** *Aging cell* 2020; 19(2):e13067.

- 400 28. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. **Hypoxia-inducible factor 1 and dysregulated c-**  
401 **Myc cooperatively induce vascular endothelial growth factor and metabolic switches**  
402 **hexokinase 2 and pyruvate dehydrogenase kinase 1.** *Mol Cell Biol* 2007; 27(21):7381-7393.
- 403 29. Delgado T, Carroll PA, Punjabi AS, Margineantu D, Hockenbery DM, Lagunoff M. **Induction of**  
404 **the Warburg effect by Kaposi's sarcoma herpesvirus is required for the maintenance of latently**  
405 **infected endothelial cells.** *Proc Natl Acad Sci U S A* 2010; 107(23):10696-10701.
- 406 30. Siska PJ, Beckermann KE, Mason FM, Andrejeva G, Greenplate AR, Sendor AB, Chiang YJ,  
407 Corona AL, Gemta LF, Vincent BG, Wang RC, Kim B, Hong J, Chen CL, Bullock TN, Irish JM, Rathmell  
408 WK, Rathmell JC. **Mitochondrial dysregulation and glycolytic insufficiency functionally impair**  
409 **CD8 T cells infiltrating human renal cell carcinoma.** *JCI Insight* 2017; 2(12).
- 410 31. Krown SE, Metroka C, Wernz JC. **Kaposi's sarcoma in the acquired immune deficiency**  
411 **syndrome: a proposal for uniform evaluation, response, and staging criteria.** **AIDS Clinical Trials**  
412 **Group Oncology Committee.** *Journal of clinical oncology : official journal of the American Society*  
413 *of Clinical Oncology* 1989; 7(9):1201-1207.
- 414 32. Roederer M. **Interpretation of cellular proliferation data: avoid the panglossian.** *Cytometry*  
415 *Part A : the journal of the International Society for Analytical Cytology* 2011; 79(2):95-101.
- 416 33. Clutton G, Mollan K, Hudgens M, Goonetilleke N. **A Reproducible, Objective Method Using**  
417 **MitoTracker(R) Fluorescent Dyes to Assess Mitochondrial Mass in T Cells by Flow Cytometry.**  
418 *Cytometry Part A : the journal of the International Society for Analytical Cytology* 2019; 95(4):450-  
419 456.
- 420 34. Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, Effros RB, Dock J, Dollard SG,  
421 Deeks SG, Martin JN, Maurer TA. **Immunosenescence is associated with presence of Kaposi's**  
422 **sarcoma in antiretroviral treated HIV infection.** *AIDS* 2013; 27(11):1735-1742.

- 423 35. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, Dong T, Chesney G, Waters A,  
424 Easterbrook P, Dunbar PR, Shepherd D, Cerundolo V, Emery V, Griffiths P, Conlon C, McMichael  
425 AJ, Richman DD, Rowland-Jones SL, Appay V. **Immune activation and CD8+ T-cell differentiation**  
426 **towards senescence in HIV-1 infection.** *PLoS Biol* 2004; 2(2):E20.
- 427 36. Paley MA, Kroy DC, Odorizzi PM, Johnnidis JB, Dolfi DV, Barnett BE, Bikoff EK, Robertson EJ,  
428 Lauer GM, Reiner SL, Wherry EJ. **Progenitor and terminal subsets of CD8+ T cells cooperate to**  
429 **contain chronic viral infection.** *Science* 2012; 338(6111):1220-1225.
- 430 37. Hasley RB, Hong C, Li W, Friesen T, Nakamura Y, Kim GY, Park JH, Hixon JA, Durum S, Hu Z,  
431 Sneller MC, Oguariri R, Imamichi T, Lane HC, Catalfamo M. **HIV immune activation drives**  
432 **increased Eomes expression in memory CD8 T cells in association with transcriptional**  
433 **downregulation of CD127.** *Aids* 2013; 27(12):1867-1877.
- 434 38. van der Windt GJ, O'Sullivan D, Everts B, Huang SC, Buck MD, Curtis JD, Chang CH, Smith AM,  
435 Ai T, Faubert B, Jones RG, Pearce EJ, Pearce EL. **CD8 memory T cells have a bioenergetic**  
436 **advantage that underlies their rapid recall ability.** *Proc Natl Acad Sci U S A* 2013; 110(35):14336-  
437 14341.
- 438 39. Bengsch B, Johnson AL, Kurachi M, Odorizzi PM, Pauken KE, Attanasio J, Stelekati E, McLane  
439 LM, Paley MA, Delgoffe GM, Wherry EJ. **Bioenergetic Insufficiencies Due to Metabolic Alterations**  
440 **Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8+ T Cell Exhaustion.**  
441 *Immunity* 2016.
- 442 40. van den Berg HA, Wooldridge L, Laugel B, Sewell AK. **Coreceptor CD8-driven modulation of T**  
443 **cell antigen receptor specificity.** *J Theor Biol* 2007; 249(2):395-408.
- 444 41. Wooldridge L, Laugel B, Ekeruche J, Clement M, van den Berg HA, Price DA, Sewell AK. **CD8**  
445 **controls T cell cross-reactivity.** *J Immunol* 2010; 185(8):4625-4632.

- 446 42. Park JH, Adoro S, Lucas PJ, Sarafova SD, Alag AS, Doan LL, Erman B, Liu X, Ellmeier W, Bosselut  
447 R, Feigenbaum L, Singer A. **'Coreceptor tuning': cytokine signals transcriptionally tailor CD8**  
448 **coreceptor expression to the self-specificity of the TCR.** *Nat Immunol* 2007; 8(10):1049-1059.
- 449 43. Lachmann R, Bajwa M, Vita S, Smith H, Cheek E, Akbar A, Kern F. **Polyfunctional T cells**  
450 **accumulate in large human cytomegalovirus-specific T cell responses.** *J Virol* 2012; 86(2):1001-  
451 1009.
- 452 44. Balyan R, Gund R, Chawla AS, Khare SP, Pradhan SJ, Rane S, Galande S, Durdik JM, George A,  
453 Bal V, Rath S. **Correlation of Cell-Surface CD8 Levels with Function, Phenotype and**  
454 **Transcriptome of Naive CD8 T Cells.** *Immunology* 2018.
- 455 45. Eller MA, Goonetilleke N, Tassaneetrithep B, Eller LA, Costanzo MC, Johnson S, Betts MR,  
456 Krebs SJ, Slike BM, Nitayaphan S, Rono K, Tovanabutra S, Maganga L, Kibuuka H, Jagodzinski L,  
457 Peel S, Rolland M, Marovich MA, Kim JH, Michael NL, Robb ML, Streeck H. **Expansion of Inefficient**  
458 **HIV-Specific CD8 T Cells during Acute Infection.** *J Virol* 2016; 90(8):4005-4016.
- 459 46. Falanga YT, Frascoli M, Kaymaz Y, Forconi C, Ong'echa JM, Bailey JA, Berg LJ, Moormann AM.  
460 **High pathogen burden in childhood promotes the development of unconventional innate-like**  
461 **CD8+ T cells.** *JCI Insight* 2017; 2(15).
- 462 47. Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S, Wikby A, Strindhall J, Franceschi  
463 C, Pawelec G. **Cytomegalovirus infection: a driving force in human T cell immunosenescence.**  
464 *Ann N Y Acad Sci* 2007; 1114:23-35.
- 465 48. Henson SM, Lanna A, Riddell NE, Franzese O, Macaulay R, Griffiths SJ, Puleston DJ, Watson AS,  
466 Simon AK, Tooze SA, Akbar AN. **p38 signaling inhibits mTORC1-independent autophagy in**  
467 **senescent human CD8(+) T cells.** *J Clin Invest* 2014; 124(9):4004-4016.

- 468 49. Dumauthioz N, Tschumi B, Wenes M, Marti B, Wang H, Franco F, Li W, Lopez-Mejia IC, Fajas L,  
469 Ho PC, Donda A, Romero P, Zhang L. **Enforced PGC-1alpha expression promotes CD8 T cell**  
470 **fitness, memory formation and antitumor immunity.** *Cellular & molecular immunology* 2020.
- 471 50. Compston LI, Li C, Sarkodie F, Owusu-Ofori S, Opare-Sem O, Allain JP. **Prevalence of persistent**  
472 **and latent viruses in untreated patients infected with HIV-1 from Ghana, West Africa.** *Journal of*  
473 *medical virology* 2009; 81(11):1860-1868.
- 474